The Impact of Newer Treatment Modalities on Survival in Patients With Hepatocellular Carcinoma

Clinical Gastroenterology and Hepatology

Volumn 4, Issue 9, 2006, Pages 1177-1183

  Taura, Naota ^a   Hamasaki, Keisuke ^a   Nakao, Kazuhiko ^a   Ichikawa, Tatsuki ^a   Nishimura, Daisuke ^a   Goto, Takashi ^a   Fukuta, Mariko ^a   Kawashimo, Hiroshi ^a   Fujimoto, Masumi ^a   Kusumoto, Koichiro ^a   Motoyoshi, Yasuhide ^a   Shibata, Hidetaka ^a   Eguchi, Katsumi ^a  

^a NAGASAKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CHEMOEMBOLIZATION; COHORT ANALYSIS; FEMALE; HUMAN; HUMAN TISSUE; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; METASTASIS; PROGNOSIS; SCORING SYSTEM; SURVIVAL RATE; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; COHORT STUDIES; ETHANOL; FEMALE; HEPATECTOMY; HUMANS; JAPAN; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; SOLVENTS; SURVIVAL RATE;

EID: 33748137646     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2006.06.008     Document Type: Article

References (33)

1. Bosch F.X., Ribes J., Cleries R., et al. Epidemiology of hepatocellular carcinoma. Clin Liver Dis 9 (2005) 191-211
2. El-Serag H.B., and Mason A.C. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 340 (1999) 745-750
3. El-Serag H.B., Mason A.C., and Key C. Trends in survival of patients with hepatocellular carcinoma between 1977 and 1996 in the United States. Hepatology 33 (2001) 62-65
4. Kiyosawa K., and Tanaka E. Characteristics of hepatocellular carcinoma in Japan. Oncology 62 Suppl 1 (2002) 5-7
5. Kiyosawa K., Umemura T., Ichijo T., et al. Hepatocellular carcinoma: recent trends in Japan. Gastroenterology 127 (2004) S17-S26
6. Kudo M., Chung H., and Osaki Y. Prognostic staging system for hepatocellular carcinoma (CLIP score): its value and limitations, and a proposal for a new staging system, the Japan Integrated Staging Score (JIS score). Hepatology 40 (2003) 207-215
7. Kudo M., Chung H., Haji S., et al. Validation of a new prognostic staging system for hepatocellular carcinoma: the JIS score compared with the CLIP score. Prognostic staging system for hepatocellular carcinoma (CLIP score): its value and limitations, and a proposal for a new staging system, the Japan Integrated Staging Score (JIS score). Hepatology 40 (2004) 1396-1405
8. Song T.J., Ip E.W., and Fong Y. Hepatocellular carcinoma: current surgical management. Gastroenterology 127 (2004) S248-S260
9. Omata M., Tateishi R., Yoshida H., et al. Treatment of hepatocellular carcinoma by percutaneous tumor ablation methods: ethanol injection therapy and radiofrequency ablation. Gastroenterology 127 (2004) S159-S166
10. Befeler A.S., Hayashi P.H., and Di Bisceglie A.M. Liver transplantation for hepatocellular carcinoma. Gastroenterology 128 (2005) 1752-1764
11. Lu D.S., Yu N.C., Raman S.S., et al. Percutaneous radiofrequency ablation of hepatocellular carcinoma as a bridge to liver transplantation. Hepatology 41 (2005) 1130-1137
12. Tateishi R., Shiina S., Teratani T., et al. Percutaneous radiofrequency ablation for hepatocellular carcinoma. An analysis of 1000 cases. Cancer 103 (2005) 1201-1209
13. Lencioni R., Cioni D., Crocetti L., et al. Early-stage hepatocellular carcinoma in patients with cirrhosis: long-term results of percutaneous image-guided radiofrequency ablation. Radiology 234 (2005) 961-967
14. Taura N., Hamasaki K., Nakao K., et al. Clinical benefits of hepatocellular carcinoma surveillance: a single-center, hospital-based study. Oncol Rep 14 (2005) 999-1003
15. Daniele B., Bencivenga A., Megna A.S., et al. Alpha-fetoprotein and ultrasonography screening for hepatocellular carcinoma. Gastroenterology 127 (2004) S108-S112
16. Di Bisceglie A.M. Issues in screening and surveillance for hepatocellular carcinoma. Gastroenterology 127 (2004) S104-S107
17. Llovet J.M., Real M.I., Montana X., et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 359 (2002) 1734-1739
18. Lo C.M., Ngan H., Tso W.K., et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 35 (2002) 1164-1171
19. GETCH: A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. Groupe d'Etude et de Traitement du Carcinome Hepatocellulaire. N Engl J Med 332 (1995) 1256-1261
20. Bruix J., Llovet J.M., Castells A., et al. Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: results of a randomized, controlled trial in a single institution. Hepatology 27 (1998) 1578-1583
21. Bruix J., Sala M., and Llovet J.M. Chemoembolization for hepatocellular carcinoma. Gastroenterology 127 (2004) S179-S188
22. Fujimoto T. The experimental and clinical studies of percutaneous ethanol injection (PEIT) under ultrasonography for small hepatocellular carcinoma. Acta Hepatol Jpn 29 (1988) 52-59
23. Shiina S., Teratani T., Obi S., et al. Percutaneous ethanol injection therapy for liver tumors. Eur J Ultrasound 13 (2001) 95-106
24. Sangiovanni A., Del Ninno E., Fasani P., et al. Increased survival of cirrhotic patients with a hepatocellular carcinoma detected during surveillance. Gastroenterology 126 (2004) 1005-1014
25. El-Serag H.B., and Everhart J.E. Improved survival after variceal hemorrhage over an 11-year period in the Department of Veterans Affairs. Am J Gastroenterol 95 (2000) 3566-3573
26. McCormick P.A., and O'Keefe C. Improving prognosis following a first variceal haemorrhage over four decades. Gut 49 (2001) 682-685
27. Marchesini G., Bianchi G., Merli M., et al. Nutritional supplementation with branched-chain amino acids in advanced cirrhosis: a double-blind, randomized trial. Effects of hyperglycaemia and hyperinsulinaemia on plasma amino acid levels in obese subjects with normal glucose tolerance. Gastroenterology 124 (2003) 1792-1801
28. Marchesini G., Marzocchi R., Noia M., et al. Branched-chain amino acid supplementation in patients with liver diseases. J Nutr 135 (2005) 1596S-1601S
29. Shiina S., Teratani T., Obi S., et al. A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma. Gastroenterology 129 (2005) 122-130
30. Goin J.E., Salem R., Carr B.I., et al. Treatment of unresectable hepatocellular carcinoma with intrahepatic yttrium 90 microspheres: a risk-stratification analysis. J Vasc Interv Radiol 16 (2005) 195-203
31. Butterfield L.H. Immunotherapeutic strategies for hepatocellular carcinoma. Gastroenterology 127 (2004) S232-S241
32. Geschwind J.F., Salem R., Carr B.I., et al. Yttrium-90 microspheres for the treatment of hepatocellular carcinoma. Gastroenterology 127 (2004) S194-S205
33. Bush D.A., Hillebrand D.J., Slater J.M., et al. High-dose proton beam radiotherapy of hepatocellular carcinoma: preliminary results of a phase II trial. Gastroenterology 127 (2004) S189-S193